NeuroSense Therapeutics is set to commence a Phase I pharmacokinetic study of its combination therapy, PrimeC, for amyotrophic lateral sclerosis (ALS) in healthy adult subjects in the US.

The move comes after the company obtained clearance for its Investigational New Drug application (IND) from the US Food and Drug Administration (FDA).

A new extended-release oral formulation, PrimeC consists of a fixed-dose cocktail of ciprofloxacin and celecoxib drugs, which are approved by the FDA. 

It can synergistically act on various crucial mechanisms of ALS that cause degeneration of motor neurons, inflammation, build-up of iron and impaired regulation of ribonucleic acid (RNA). 

This approach potentially aids in hindering ALS progression.

The randomised, open-label, single-dose, three treatment, three-period crossover pharmacokinetic trial will analyse the effect of food on PrimeC’s bioavailability versus bioavailability of ciprofloxacin plus celecoxib in 12 healthy adult participants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A Phase IIa trial of PrimeC concluded recently had met the safety and efficacy endpoints including lowering functional and respiratory deterioration.

PrimeC also offered statistically significant changes in ALS-associated biological markers signifying the oral therapy’s biological activity. 

The company intends to commence a multinational, double-blind, placebo-controlled Phase IIb trial of an optimised dose and updated formulation of PrimeC in the second quarter of this year. 

NeuroSense CEO Alon Ben-Noon said: “Data from our Phase IIa clinical study confirmed that PrimeC is a novel therapy with the potential to help people with ALS and address a $3bn market in need of a more effective treatment. 

“As we prepare to initiate our Phase IIb study in the next few months, the goal of our pharmacokinetic study under FDA IND is to generate additional data on the bioavailability of PrimeC as it relates to food intake in healthy individuals.”

An incurable neurodegenerative ailment, ALS leads to complete paralysis and death within two to five years of diagnosis.